Physician profile
Michael Dragutsky
NPI 1851372213
$7,569.02
in general payments reported to CMS, 2019-2025
23 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $155 · 2021: $3,206 · 2022: $547 · 2023: $420 · 2024: $1,989 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490 · Consulting Fee: $1,396 · Education: $32.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.65 |
| Consulting Fee | $1,396.00 |
| Education | $32.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,570.17 | 2021-2024 | |
| Abbvie INC. | $606.36 | 2019-2025 | Rinvoq, Skyrizi |
| Intercept Pharmaceuticals, INC. | $312.01 | 2019-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $258.02 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $241.67 | 2019-2025 | |
| Celgene Corporation | $230.40 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $228.88 | 2019-2020 | |
| Pfizer INC. | $213.61 | 2019-2025 | |
| Madrigal Pharmaceuticals | $144.79 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $130.39 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $126.87 | 2024 | Iqirvo |
| Medtronic, INC. | $117.78 | 2021-2022 | |
| Micro-Tech Endoscopy USA, INC. | $83.67 | 2020-2025 | Lesionhunter, Snares, Irrigation Tubing |
| Ucb, INC. | $52.73 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $50.28 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.36 | 2019 | |
| Janssen Biotech, INC. | $42.20 | 2019-2023 | Stelara |
| Qol Medical, LLC | $38.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $16.78 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.97 | 2023 | |
| Olympus America INC. | $14.53 | 2020 | |
| Janssen Scientific Affairs, LLC | $13.55 | 2019 | |
| Shire North American Group INC | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dragutsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.